BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Buy” from Brokerages
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given an average recommendation of “Buy” by the ten brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.00.
BCRX has been the subject of several recent analyst reports. Noble Financial restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Saturday, May 6th. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Monday, May 1st. Needham & Company LLC restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, May 19th. Finally, BidaskClub upgraded shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st.
ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/biocryst-pharmaceuticals-inc-nasdaqbcrx-receives-average-recommendation-of-buy-from-brokerages.html.
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 1.81% during mid-day trading on Tuesday, reaching $4.50. The company’s stock had a trading volume of 620,143 shares. The firm’s 50 day moving average is $5.61 and its 200-day moving average is $6.36. BioCryst Pharmaceuticals has a one year low of $3.73 and a one year high of $9.25. The stock’s market cap is $361.89 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. BioCryst Pharmaceuticals’s revenue was down 35.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.22) earnings per share. Equities analysts expect that BioCryst Pharmaceuticals will post ($0.72) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after buying an additional 1,651,292 shares in the last quarter. RA Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 16.7% in the first quarter. RA Capital Management LLC now owns 3,489,795 shares of the biotechnology company’s stock worth $29,314,000 after buying an additional 500,000 shares in the last quarter. State Street Corp boosted its position in BioCryst Pharmaceuticals by 8.6% in the first quarter. State Street Corp now owns 2,272,104 shares of the biotechnology company’s stock worth $19,083,000 after buying an additional 179,216 shares in the last quarter. Jennison Associates LLC boosted its position in BioCryst Pharmaceuticals by 12.8% in the second quarter. Jennison Associates LLC now owns 2,080,818 shares of the biotechnology company’s stock worth $11,569,000 after buying an additional 236,182 shares in the last quarter. Finally, FMR LLC boosted its position in BioCryst Pharmaceuticals by 97.5% in the first quarter. FMR LLC now owns 1,456,885 shares of the biotechnology company’s stock worth $12,238,000 after buying an additional 719,162 shares in the last quarter. 84.49% of the stock is owned by institutional investors and hedge funds.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.